Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative.

Wah-Kheong ChanS TreeprasertsukK ImajoHirokazu TakahashiY SekiK KasamaS KakizakiJ-G FanMyeong Jun SongS K YoonY-Y DanL LesmanaK-Y HoK-L GohVincent Wai-Sun Wong

Published in: Alimentary pharmacology & therapeutics (2018)

More severe liver disease can be suspected or ruled out based on factors identified in this study. Utilisation of structured lifestyle program, vitamin E and pioglitazone was limited despite this being a cohort of biopsy-proven NAFLD patients with majority of patients having NASH.

Keyphrases

end stage renal disease
quality improvement
ejection fraction
chronic kidney disease
metabolic syndrome
cardiovascular disease
pulmonary embolism
prognostic factors
peritoneal dialysis
type diabetes
patient reported outcomes
combination therapy
fine needle aspiration